Stem cell researchers can start taking advantage of the power of benchtop cell sorters and their ability to improve results.
Single use technologies are expected to play a big role in the commercialization of cell and gene therapies because of their cost, speed, and sterility benefits. In some ways, will cell and gene therapy manufacturing be similar to biopharmaceutical manufacturing? What are the key differences and gaps in learning?
Single use connection technologies are expected to play a critical role in commercial manufacturing of cell and gene therapies. Learn about the types of connection technologies, selection considerations, and the impact of the setting on connection technology.
The routine application of human pluripotent stem cells and their derivatives in regenerative medicine and innovative drug discovery will require the constant supply of high cell numbers in consistent, high quality.
This application note details the suitability of Eppendorf BioBLU 0.3c Single-Use Vessels controlled by a DASbox Mini Bioreactor System for the expansion of human bone marrow-derived mesenchymal stem cells on microcarriers.
Solving the bottleneck in gene therapy of manufacturing of viral material at sufficient cost and scale.
Helpful methodology that can be applied to the large-scale expansion of other cell types for use in various applications using Cell Factory systems.
Testing for evidence of microbial contamination in bioprocessing has a long history — and can be expensive, slow, and burdensome. So suppliers, testing facilities, and regulators have been seeking improvements.
By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.
With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.